New Covid drug can work against all mutations of Omicron variant, latest data suggests 

- Advertisement -


  • Lab studies show sotrovimab to be effective against 37 known mutations of the new strain
  • Data last week indicated that the drug could counteract several key mutations of Omicron
  • New data means the treatment will work against the variant in all its forms.
  • The drug was approved last week after it was revealed that it had cut hospitalizations and deaths by 79 percent in patients with mild to moderate COVID symptoms.

- Advertisement -

According to new data, a COVID antibody treatment has been shown to work against all mutations of the Omicron type.

Lab studies have shown that the drug called sotrovimab, developed by British pharma giant GlaxoSmithKline with US firm Vir Biotechnology, is effective against 37 currently known mutations of the new strain.

advertisement

Data last week indicated that sotrovimab was able to counteract multiple dominant mutations of Omicron. But the new data means the treatment will work against the variant in all its forms.

And the drug was approved by the UK’s Medicines and Healthcare products Regulatory Agency last week after trials showed it reduced the chances of hospitalization and death by 79 percent in patients with mild to moderate COVID symptoms.

- Advertisement -

Lab studies have shown that the drug called sotrovimab, developed by British pharma giant GlaxoSmithKline with US firm Vir Biotechnology, is effective against 37 currently known mutations of the new strain.

Sotrovimab, sold under the brand name Xevudy, is used to prevent people from developing severe COVID cases and is useful for people with weakened immune systems. It gives the body antibodies to fight the disease while antivirals interfere with the virus’s reproduction.

The UK government has already ordered around 100,000 doses.

MHRA authorization means it has now approved two antibody treatments, Ronaprev and Zevudy, and an antiviral, Legevio, also known as molanupiravir.

The new data may be greeted with relief by many public health experts amid ongoing uncertainty about whether existing COVID-19 vaccines and treatments can effectively fight against omicrons.

There was also a second dose of good news with the plant-based COVID-19 vaccine developed by GSK in association with Canadian biotech Medicago, which was 71 per cent effective against multiple variants of Covid-19 and 75 pc effective against the highly infectious Delta. the stress.

The trial also showed that 24,000 people in the study had no serious adverse reactions to the vaccine.

The trial also showed that 24,000 people in the study had no serious adverse reactions to the vaccine.

The trial also showed that 24,000 people in the study had no serious adverse reactions to the vaccine.

As a result of the data, GSK and Medicago plan to request approval for the jab from Canadian regulators.

If given the green signal, it would become the world’s first plant-based COVID-19 vaccine authorized for human use.

Plant-based drugs can be produced rapidly and in large quantities, making them useful for large-scale public health campaigns and vaccination campaigns.

The GSK-Medicago vaccine can also be stored at refrigerator temperature, making it easier to transport than some existing vaccines such as those developed by Pfizer and BioNTech, which need to be stored at -70°C .

- Advertisement -
Mail Us For  DMCA / Credit  Notice

Recent Articles

Stay on top - Get the daily news in your inbox

Related Stories